Purnak S, et al. - Experts reviewed their experience with single-agent etoposide in the treatment of advanced-stage or refractory early-stage mycosis fungoides (MF) with focus on analyzing its efficacy and safety. They identified patients through the Cutaneous T Cell Lymphoma Database of Indiana University that involved patients treated from 2006 to 2016. Findings demonstrated that for MF, etoposide was an effective treatment and could be considered in selected patients with progressive MF who failed other treatments.